Image for About NeoStem

About NeoStem

NeoStem develops and manufactures cell therapies for its proprietary technology platforms and for the cell therapy industry.

Learn More



Image for Targeted Immunotherapy

Targeted Immunotherapy

NeoStem has announced signing of a definitive agreement to acquire California Stem Cell, Inc., to target the cancer initiating cells, starting with a Phase 3 trial for melanoma.

Learn More by reading our press release

Enhancingthe body’s healing response.

Image for Ischemic Repair

Ischemic Repair

NeoStem is developing therapies to repair ischemia through the development and formation of new blood vessels.

Learn More

Rebalancingthe immune system.

Image for Immune Modulation

Immune Modulation

NeoStem seeks to develop cell therapies using a person’s own immune cells as a therapeutic product to treat disorders of the immune system.

Learn More

Unlockingthe power of VSELs.

Image for Tissue Regeneration

Tissue Regeneration

NeoStem is exploring the therapeutic potential of very small embryonic-like stem cells (VSELsTM) to regenerate or repair damaged or diseased tissues.

Learn More

Leveragingexperience in cell therapy.

Image for Contract Manufacturing

Contract Manufacturing

NeoStem’s subsidiary, PCT, provides outsourced manufacturing capabilities to the cell therapy industry while supporting the development of NeoStem’s proprietary cell therapy products.

Learn More

News + Events

News + Events

NeoStem Announces Definitive Agreement to Acquire California Stem Cell, Inc. April 14, 2014 - Learn More


NeoStem Welcomes Dr. Adel Nada as Vice President, Immunotherapy April 3, 2014 - Learn More


NeoStem and Progenitor Cell Therapy (PCT) to Present at Multiple April Conferences April 1, 2014 - Learn More

See All

NeoStem Blog

Continued Growth through Strategic Acquisitions

Since NeoStem was founded in 2006, I have had the immense pleasure as Chairman and CEO of overseeing the gr.... Read More

An Update from Dr. Robin Smith, Chairman and CEO

Greetings from NeoStem where we have recently filed our Company’s 2013 Annual Report on form 10-k, which .... Read More